Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2023-2027

Report ID: 1013190 | Published Date: Jan 2025 | No. of Page: 105 | Base Year: 2024 | Rating: 3.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Obeticholic acid（OCA）
        1.2.3 Selonsertib
    1.3 Market by Application
        1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital Pharmacy
        1.3.3 Online Provider
        1.3.4 Retail Pharmacy
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2016-2027)
    2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Regions
        2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Share by Regions (2016-2021)
        2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2022-2027)
    2.3 Nonalcoholic Steatohepatitis (NASH) Industry Dynamic
        2.3.1 Nonalcoholic Steatohepatitis (NASH) Market Trends
        2.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers
        2.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
        2.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue
        3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2016-2021)
        3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2016-2021)
    3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
    3.4 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
        3.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2020
    3.5 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
    3.6 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
    3.7 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Type
    4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2016-2021)
    4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2022-2027)

5 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Application
    5.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2016-2021)
    5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
    6.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
        6.2.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
        6.2.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
        6.2.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
    6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
        6.3.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
        6.3.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
        6.3.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
    6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
        6.4.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021)
        6.4.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
    7.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type
        7.2.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
        7.2.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
        7.2.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
    7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application
        7.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
        7.3.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
        7.3.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
    7.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
        7.4.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021)
        7.4.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
    8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type
        8.2.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
    8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application
        8.3.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
    8.4 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region
        8.4.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
    9.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
        9.2.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
        9.2.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
        9.2.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
    9.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
        9.3.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
        9.3.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
        9.3.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
    9.4 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
        9.4.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021)
        9.4.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2016-2027)
    10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type
        10.2.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2027)
    10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application
        10.3.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2027)
    10.4 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country
        10.4.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 AstraZeneca
        11.1.1 AstraZeneca Company Details
        11.1.2 AstraZeneca Business Overview
        11.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Introduction
        11.1.4 AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.1.5 AstraZeneca Recent Development
    11.2 Arena Pharmaceuticals
        11.2.1 Arena Pharmaceuticals Company Details
        11.2.2 Arena Pharmaceuticals Business Overview
        11.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
        11.2.4 Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.2.5 Arena Pharmaceuticals Recent Development
    11.3 GSK
        11.3.1 GSK Company Details
        11.3.2 GSK Business Overview
        11.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Introduction
        11.3.4 GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.3.5 GSK Recent Development
    11.4 Novo Nordisk
        11.4.1 Novo Nordisk Company Details
        11.4.2 Novo Nordisk Business Overview
        11.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Introduction
        11.4.4 Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.4.5 Novo Nordisk Recent Development
    11.5 Roche
        11.5.1 Roche Company Details
        11.5.2 Roche Business Overview
        11.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Introduction
        11.5.4 Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.5.5 Roche Recent Development
    11.6 Vivus
        11.6.1 Vivus Company Details
        11.6.2 Vivus Business Overview
        11.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Introduction
        11.6.4 Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.6.5 Vivus Recent Development
    11.7 Arisaph Pharmaceuticals
        11.7.1 Arisaph Pharmaceuticals Company Details
        11.7.2 Arisaph Pharmaceuticals Business Overview
        11.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
        11.7.4 Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.7.5 Arisaph Pharmaceuticals Recent Development
    11.8 Cempra Pharmaceuticals
        11.8.1 Cempra Pharmaceuticals Company Details
        11.8.2 Cempra Pharmaceuticals Business Overview
        11.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
        11.8.4 Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.8.5 Cempra Pharmaceuticals Recent Development
    11.9 Galectin Therapeutics
        11.9.1 Galectin Therapeutics Company Details
        11.9.2 Galectin Therapeutics Business Overview
        11.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
        11.9.4 Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.9.5 Galectin Therapeutics Recent Development
    11.10 Galmed Pharmaceuticals
        11.10.1 Galmed Pharmaceuticals Company Details
        11.10.2 Galmed Pharmaceuticals Business Overview
        11.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
        11.10.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.10.5 Galmed Pharmaceuticals Recent Development
    11.11 Genfit
        11.11.1 Genfit Company Details
        11.11.2 Genfit Business Overview
        11.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
        11.11.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.11.5 Genfit Recent Development
    11.12 Gilead
        11.12.1 Gilead Company Details
        11.12.2 Gilead Business Overview
        11.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Introduction
        11.12.4 Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
        11.12.5 Gilead Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Obeticholic acid（OCA）
    Table 3. Key Players of Selonsertib
    Table 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2016-2021)
    Table 8. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2022-2027)
    Table 10. Nonalcoholic Steatohepatitis (NASH) Market Trends
    Table 11. Nonalcoholic Steatohepatitis (NASH) Market Drivers
    Table 12. Nonalcoholic Steatohepatitis (NASH) Market Challenges
    Table 13. Nonalcoholic Steatohepatitis (NASH) Market Restraints
    Table 14. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players (2016-2021)
    Table 16. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2020)
    Table 17. Ranking of Global Top Nonalcoholic Steatohepatitis (NASH) Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
    Table 21. Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2016-2021)
    Table 25. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Nonalcoholic Steatohepatitis (NASH) Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2016-2021)
    Table 29. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. AstraZeneca Company Details
    Table 62. AstraZeneca Business Overview
    Table 63. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product
    Table 64. AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 65. AstraZeneca Recent Development
    Table 66. Arena Pharmaceuticals Company Details
    Table 67. Arena Pharmaceuticals Business Overview
    Table 68. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
    Table 69. Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 70. Arena Pharmaceuticals Recent Development
    Table 71. GSK Company Details
    Table 72. GSK Business Overview
    Table 73. GSK Nonalcoholic Steatohepatitis (NASH) Product
    Table 74. GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 75. GSK Recent Development
    Table 76. Novo Nordisk Company Details
    Table 77. Novo Nordisk Business Overview
    Table 78. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product
    Table 79. Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 80. Novo Nordisk Recent Development
    Table 81. Roche Company Details
    Table 82. Roche Business Overview
    Table 83. Roche Nonalcoholic Steatohepatitis (NASH) Product
    Table 84. Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 85. Roche Recent Development
    Table 86. Vivus Company Details
    Table 87. Vivus Business Overview
    Table 88. Vivus Nonalcoholic Steatohepatitis (NASH) Product
    Table 89. Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 90. Vivus Recent Development
    Table 91. Arisaph Pharmaceuticals Company Details
    Table 92. Arisaph Pharmaceuticals Business Overview
    Table 93. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
    Table 94. Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 95. Arisaph Pharmaceuticals Recent Development
    Table 96. Cempra Pharmaceuticals Company Details
    Table 97. Cempra Pharmaceuticals Business Overview
    Table 98. Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 99. Cempra Pharmaceuticals Recent Development
    Table 100. Galectin Therapeutics Company Details
    Table 101. Galectin Therapeutics Business Overview
    Table 102. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product
    Table 103. Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 104. Galectin Therapeutics Recent Development
    Table 105. Galmed Pharmaceuticals Company Details
    Table 106. Galmed Pharmaceuticals Business Overview
    Table 107. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
    Table 108. Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 109. Galmed Pharmaceuticals Recent Development
    Table 110. Genfit Company Details
    Table 111. Genfit Business Overview
    Table 112. Genfit Nonalcoholic Steatohepatitis (NASH) Product
    Table 113. Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 114. Genfit Recent Development
    Table 115. Gilead Company Details
    Table 116. Gilead Business Overview
    Table 117. Gilead Nonalcoholic Steatohepatitis (NASH) Product
    Table 118. Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021) & (US$ Million)
    Table 119. Gilead Recent Development
    Table 120. Research Programs/Design for This Report
    Table 121. Key Data Information from Secondary Sources
    Table 122. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Type: 2020 VS 2027
    Figure 2. Obeticholic acid（OCA） Features
    Figure 3. Selonsertib Features
    Figure 4. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2020 VS 2027
    Figure 5. Hospital Pharmacy Case Studies
    Figure 6. Online Provider Case Studies
    Figure 7. Retail Pharmacy Case Studies
    Figure 8. Nonalcoholic Steatohepatitis (NASH) Report Years Considered
    Figure 9. Global Nonalcoholic Steatohepatitis (NASH) Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 10. Global Nonalcoholic Steatohepatitis (NASH) Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions: 2020 VS 2027
    Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2022-2027)
    Figure 13. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players in 2020
    Figure 14. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2020
    Figure 15. The Top 10 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2020
    Figure 16. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2016-2021)
    Figure 17. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2022-2027)
    Figure 18. North America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 19. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
    Figure 20. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
    Figure 21. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2016-2027)
    Figure 22. United States Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Canada Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
    Figure 26. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
    Figure 27. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2016-2027)
    Figure 28. Germany Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. France Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. U.K. Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Italy Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Russia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Nordic Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
    Figure 36. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
    Figure 37. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2016-2027)
    Figure 38. China Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Japan Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. South Korea Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. India Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Australia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
    Figure 46. Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
    Figure 47. Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2016-2027)
    Figure 48. Mexico Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Brazil Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2016-2027)
    Figure 52. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2016-2027)
    Figure 53. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2016-2027)
    Figure 54. Turkey Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. UAE Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. AstraZeneca Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 58. Arena Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 59. GSK Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 60. Novo Nordisk Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 61. Roche Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 62. Vivus Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 63. Arisaph Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 64. Cempra Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 65. Galectin Therapeutics Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 66. Galmed Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 67. Genfit Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 68. Gilead Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2016-2021)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Frequently Asked Questions
Nonalcoholic Steatohepatitis (NASH) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Nonalcoholic Steatohepatitis (NASH) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Nonalcoholic Steatohepatitis (NASH) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Non-relational SQL

The NoSQL Market (Not Only SQL) is a database mechanism developed for storage, analysis and acces ... Read More

Oil & Gas Security

Oil and gas security is defined as the security process in which the oil and gas operational sect ... Read More

Online Banking

Digital banking includes all kinds of online/internet transactions done for various purposes.� ... Read More